The Prevalence and Clinical Significance of Inherited Thrombophilic Risk Factors in Patients with Antiphospholipid Syndrome

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2009 Jun 9

PMID 19504051

Citations 6

Authors

Reyhan Diz-Kucukkaya

Veysel Sabri Hancer

Bahar Artim-Esen

Yuksel Pekcelen

Murat Inanc

Affiliations

Soon will be listed here.

Abstract

In this study, we evaluated common inherited thrombophilic risk factors in patients with antiphospholipid syndrome (APS), and reviewed relevant literature. Ninety-four APS patients with documented thrombosis, 40 patients with persistent antiphospholipid antibody (aPLA) positivity but without thrombosis, and healthy controls were screened. We found that inherited protein C, protein S, and antithrombin deficiencies were rare in APS patients. The presence of factor V Leiden G506A (FVL) mutation was significantly higher in APS patients with thrombosis compared to healthy controls (11.2% versus 4.9%, P = 0.0043). The prevalence of prothrombin G20210A mutation, however was not significantly increased in APS patients with thrombosis compared to patients without thrombosis (2.7% versus 1.25%, P = 0.67). Our literature review suggested that FVL mutation was associated with both arterial and venous thrombosis but prothrombin G20210A mutation does not seem to contribute much to thrombotic risk in patients with APS. In conclusion, the presence of FVL mutation may define a small but important subgroup of patients who had high risk of both venous and arterial thrombosis. Known thrombophilic risk factors however, may influence the development of thrombotic complications in approximately 10% of APS patients. These findings may indicate that thrombotic complications in APS patients are largely related with aPLA-mediated mechanisms.

Citing Articles

Successful treatment for a patient with antiphospholipid syndrome and decreased protein S activity exacerbated by heparin-induced thrombocytopenia: A case report.

Nishihara M, Nagae H, Otake S, Asatani S, Nagasawa Y, Akiya K Medicine (Baltimore). 2024; 103(45):e40281.

PMID: 39533629 PMC: 11557061. DOI: 10.1097/MD.0000000000040281.

Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review).

Gavris C, Nedelcu L, Pascu A Exp Ther Med. 2021; 21(3):287.

PMID: 33603894 PMC: 7851644. DOI: 10.3892/etm.2021.9718.

Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphospholipid Syndrome.

Navarro-Carpentieri D, Castillo-Hernandez M, Majluf-Cruz K, Espejo-Godinez G, Carmona-Olvera P, Moreno-Hernandez M Clin Appl Thromb Hemost. 2017; 24(5):834-840.

PMID: 28884609 PMC: 6714872. DOI: 10.1177/1076029617727859.

Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Mar N, Kosowicz R, Hook K J Thromb Thrombolysis. 2014; 38(2):196-200.

PMID: 24549974 DOI: 10.1007/s11239-014-1061-x.

Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.

Jadaon M Mediterr J Hematol Infect Dis. 2012; 3:e2011037.

PMID: 22224194 PMC: 3251907. DOI: 10.4084/MJHID.2011.037.

References

Torresan M, Machado T, Siqueira L, Ozelo M, Arruda V, Annichino-Bizzacchi J . The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis. Blood Coagul Fibrinolysis. 2000; 11(7):679-82. DOI: 10.1097/00001721-200010000-00014. View

Pablos J, Caliz R, Carreira P, Atsumi T, Serrano L, Amengual O . Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J Rheumatol. 1999; 26(3):588-90. View

Fijnheer R, Horbach D, Donders R, Vile H, von Oort E, Nieuwenhuis H . Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost. 1996; 76(4):514-7. View

Forastiero R, Martinuzzo M, Adamczuk Y, Varela M, Pombo G, Carreras L . The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica. 2001; 86(7):735-41. View

Diz-Kucukkaya R, Demir K, Yenerel M, Nalcaci M, Kaymakoglu S, Inanc M . Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome. Haematologia (Budap). 2002; 32(1):73-7. DOI: 10.1163/156855902760262790. View

Levine J, Branch D, Rauch J . The antiphospholipid syndrome. N Engl J Med. 2002; 346(10):752-63. DOI: 10.1056/NEJMra002974. View

Akar N, Akar E, Dalgin G, Sozuoz A, Omurlu K, Cin S . Frequency of Factor V (1691 G --> A) mutation in Turkish population. Thromb Haemost. 1998; 78(6):1527-8. View

Rosendaal F . Venous thrombosis: a multicausal disease. Lancet. 1999; 353(9159):1167-73. DOI: 10.1016/s0140-6736(98)10266-0. View

Bertina R, Koeleman B, Koster T, Rosendaal F, Dirven R, de Ronde H . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64-7. DOI: 10.1038/369064a0. View

10.

Brandt J, Triplett D, ALVING B, Scharrer I . Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995; 74(4):1185-90. View

11.

Lockshin M, Erkan D . Treatment of the antiphospholipid syndrome. N Engl J Med. 2003; 349(12):1177-9. DOI: 10.1056/NEJMe038131. View

12.

Galli M, Finazzi G, Duca F, Norbis F, Moia M . The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol. 2000; 108(4):865-70. DOI: 10.1046/j.1365-2141.2000.01964.x. View

13.

Wilson W, Gharavi A, Koike T, Lockshin M, Branch D, Piette J . International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999; 42(7):1309-11. DOI: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F. View

14.

De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A . The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica. 2006; 91(5):695-8. View

15.

Poort S, Rosendaal F, Reitsma P, Bertina R . A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88(10):3698-703. View

16.

Hansen K, Kong D, Moore K, Ortel T . Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol. 2001; 28(9):2018-24. View

17.

Ames P, Tommasino C, DAndrea G, Iannaccone L, Brancaccio V, Margaglione M . Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies--prevalence and significance. Thromb Haemost. 1998; 79(1):46-9. View

18.

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

19.

Akar N, Misirlioglu M, Akar E, Avcu F, Yalcin A, Sozuoz A . Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol. 1998; 58(3):249. DOI: 10.1002/(sici)1096-8652(199807)58:3<249::aid-ajh20>3.0.co;2-3. View

20.

Ames P, Margaglione M, Tommasino C, Bossone A, Iannaccone L, Brancaccio V . Impact of plasma homocysteine and prothrombin G20210 A on primary antiphospholipid syndrome. Blood Coagul Fibrinolysis. 2001; 12(8):699-704. DOI: 10.1097/00001721-200112000-00012. View